Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2016-01-28

Clinical Trial Update: Rituximab and Alemtuzumab in Treating Older Patients With Progressive Chronic Lymphocytic Leukemia [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating rituximab and alemtuzumab in older patients with progressive chronic lymphocytic leukemia; study terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Alemtuzumab (Alemtuzumab)
  • Rituximab (rituximab)

Snippet

Sponsor: ECOG-ACRIN Cancer Research Group | Conditions: Chronic Lymphocytic Leukemia | Phase 2 | Status: TERMINATED | Results posted: 2016-01-28